# Sources — Benjamin Franklin

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 3, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. *The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin*, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806. Project Gutenberg eBook 48136. Its biographical account supports that he had been “little subject to disease, except an attack of the gout occasionally, until about the year 1781, when he was first attacked with symptoms of the calculous complaint, which continued during his life”; the severe pleurisy of 1735 that ended in an abscess of the left lung; and the account of his last illness by his physician, Dr. Jones: the stone “had for the last twelve months confined him chiefly to his bed,” large doses of laudanum during the painful paroxysms, the fever and left-sided chest pain about sixteen days before death, the abscess in his lungs that burst, and his death on April 17, 1790, about eleven at night, aged eighty-four. https://www.gutenberg.org/ebooks/48136
2. *Memoirs of Benjamin Franklin; Written by Himself*, Volume 2. New York: Harper & Brothers. Project Gutenberg eBook 40236. Supports his letters: to Samuel Huntington, Passy, March 12, 1781 (“the long and severe fit of the gout which I had the last winter has shaken me exceedingly”); to George Wheatley, Passy, May 23, 1785 (“the gout is bad, and … the stone is worse,” and at fourscore “subject to the gout and the stone”); to M. Veillard, Philadelphia, April 15, 1787 (“I have never had the least doubt of its being the stone,” which “has increased” but gives him no more pain than at Passy); to Mr. Jordain, May 18, 1787 (gout, stone, and old age as his three incurable maladies); and to B. Vaughan, October 24, 1788 (“recovering from a long-continued gout”). https://www.gutenberg.org/ebooks/40236
3. *The Complete Works*, Volume 2 (1806). Project Gutenberg eBook 48137. Supports his letter of July 31, 1786, on the effects of lead: in 1724, as a compositor at Palmer's printing house in London, he sometimes heated his case of type, was warned he might lose the use of his hands, and had felt “a kind of obscure pain … in the bones of my hand when working over the types made very hot.” https://www.gutenberg.org/ebooks/48137
4. *The Complete Works*, Volume 3 (1806). Project Gutenberg eBook 48138. Supports the *Dialogue between Franklin and the Gout*, headed “Midnight, October 22, 1780,” in which the Gout charges him with eating and drinking too freely and with a sedentary life. https://www.gutenberg.org/ebooks/48138
5. Franklin B. *Autobiography of Benjamin Franklin*, with notes. Project Gutenberg eBook 20203. Supports the editor's note giving his birth as “Sunday, January 6, old style, 1706,” on Milk Street, Boston; the pleurisy of February 1726/7 that “very nearly carried me off”; the deaths of his father at 89 in 1744 and his mother at 85 in 1752, neither of whom he knew to have any sickness but that of which they died; and the death of his four-year-old son of smallpox in 1736. https://www.gutenberg.org/ebooks/20203
6. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.
7. American Battlefield Trust. “Benjamin Franklin.” Supports his birth in Boston on January 17, 1706, and his death in his Philadelphia home on April 17, 1790. https://www.battlefields.org/learn/biographies/benjamin-franklin
8. Finger S, Hagemann IS. “Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning.” *Proc Am Philos Soc* 2008;152(2):189–206. PMID 19244863. The abstract supports repeated attacks of gout and a large bladder stone that caused considerable pain and markedly decreased his mobility, and lists risk factors including sex, genetics, diet, drinking, age, psoriasis, and exposure to lead. Only the abstract was read. https://pubmed.ncbi.nlm.nih.gov/19244863/
9. Mikhael M, Siva C. “‘Dialogue Between Franklin and the Gout’ Reexamined.” *Clin Med Res* 2023;21(4):196–200. PMID 38296638. The abstract states that he woke with a gout attack on October 22, 1780, and wrote the Dialogue, and that he was overweight and probably had consequences of the metabolic syndrome, including gout. Only the abstract was read. https://pubmed.ncbi.nlm.nih.gov/38296638/

## Clinical guidance

1. FitzGerald JD, et al. “2020 American College of Rheumatology Guideline for the Management of Gout.” *Arthritis Care Res* 2020;72(6):744–760. PMID 32391934. Urate-lowering therapy for two or more flares a year; allopurinol first line, started at 100 mg or less (lower in stage 4 CKD) and titrated to a serum urate below 6 mg/dL; HLA-B*58:01 testing only in patients of Southeast Asian descent and African American patients; anti-inflammatory prophylaxis for three to six months; continuing urate-lowering therapy during flares; switching hydrochlorothiazide to an alternative and preferring losartan where feasible; limiting alcohol, purines, and high-fructose corn syrup; weight loss. https://pubmed.ncbi.nlm.nih.gov/32391934/
2. Pearle MS, et al. *Medical Management of Kidney Stones: AUA Guideline* (2014, amended 2019). Stone analysis, a 24-hour urine collection for metabolic evaluation, fluids for a urine volume of at least 2.5 L a day, potassium citrate to raise urine pH in uric acid stone formers, and periodic blood testing for adverse effects of drug therapy. https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-medical-mangement-guideline
3. European Association of Urology. *EAU Guidelines on Urolithiasis*, including bladder stones: non-contrast CT, treatment of the underlying bladder outlet obstruction, transurethral cystolitholapaxy, and alkalinization for uric acid stones. https://uroweb.org/guidelines/urolithiasis
4. American Urological Association. *Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia* (2023 amendment). IPSS, uroflowmetry and post-void residual before surgery, and surgery for bladder stones secondary to obstruction. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-%28bph%29-guideline
5. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int* 2024;105(4S):S117–S314. PMID 38490803. Risk-based eGFR and albuminuria monitoring, KFRE, statins for adults 50 or older with eGFR below 60 without routine repeat lipid testing, and NSAID avoidance. https://pubmed.ncbi.nlm.nih.gov/38490803/
6. Whelton PK, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Hypertension* 2018;71(6):e13–e115. PMID 29133356. Target below 130/80 mmHg and out-of-office monitoring. https://pubmed.ncbi.nlm.nih.gov/29133356/
7. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs. Blood pressure every visit; potassium and creatinine two to four weeks after starting an ARB; a metabolic panel every six months on an ARB; eGFR and urine albumin yearly at G3a A1; calcium, phosphate, PTH, and vitamin D at baseline in G3a; hemoglobin and KFRE yearly; medication review for NSAIDs every visit; IPSS at every follow-up; residual and uroflowmetry before a procedure; post-procedural checks at one, three, six, and twelve months; PSA only when it would change management. The CMID has no gout or stone monograph. https://patrickrutledge.github.io/topthirty/
8. Centers for Medicare & Medicaid Services, Medicare Wellness Visits, and the Medicare Preventive Services reference (Aether Forge, 2026), for the subsequent annual wellness visit. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html and https://patrickrutledge.github.io/preventative_services/
9. U.S. Preventive Services Task Force: Colorectal Cancer Screening (2021), Prostate Cancer Screening (2018), Abdominal Aortic Aneurysm Screening (2019), Falls Prevention in Community-Dwelling Older Adults (2024), and Unhealthy Alcohol Use Screening and Counseling (2018). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening

## Editorial resolutions

- **Birth date.** The preferred date is the Gregorian January 17, 1706. The autobiography's note gives January 6, 1706, Old Style, the same day in the Julian calendar; it is recorded as a superseded alternative. The synthetic date of birth keeps January 17.
- **Index age.** The episode presents him at 76, the age at which the 1806 biographical account places the first symptoms of his stone (about 1781) and soon after the severe gout he described in March 1781. The synthetic date of birth is January 17, 1950, so the whole-year shift is 244 years. The index visit is March 2, 2026 (true frame March 2, 1782); the chronic-care visits follow on March 30, May 18, and September 14, 2026 (true frame March 30, May 18, and September 14, 1782); the surgery is April 20, 2026 (true frame April 20, 1782); the sick visit is July 6, 2026 (true frame July 6, 1782) and the annual wellness visit October 19, 2026 (true frame October 19, 1782). He lived to 84, so all fall within his lifetime. The visit type is `annual_wellness_subsequent` because he is 65 or older.
- **Gout and stone.** Both are documented in his own letters (**D**). The composition and cause of his historical stone are not documented. The synthetic episode makes it a uric acid bladder stone behind benign prostatic hyperplasia, a common modern combination in older men with gout; the prostate diagnosis is synthetic and does not claim that he had it. His physician's account says only “the stone”; it is recorded as a bladder stone because the roster, the 2008 review, and his own descriptions of pain with jolting travel point that way, and no kidney location is asserted.
- **Lead.** His exposure to heated type metal in 1724 and the pain in the bones of his hand are documented in his own letter (**D**). Lead poisoning as a contributor to his gout is a retrospective interpretation (**R**, possible) and is not on the problem list. The modern episode checks one synthetic blood lead level (3.1 µg/dL, below the adult reference value) to teach that blood lead reflects recent rather than lifetime exposure.
- **Kidney disease and hypertension.** No measure of his kidney function or blood pressure exists. The stage 3a chronic kidney disease and the hypertension are synthetic, added because they change gout care (allopurinol start dose, avoiding NSAIDs, replacing a thiazide with losartan). Obesity is suggested by the 2023 review (**R**, possible) and is represented only by the synthetic BMI.
- **Family history.** The autobiography gives his parents' ages at death and his son's death from smallpox. Causes for his parents are not recorded, and nothing is attributed to any relative beyond what the source states.
- **Not used.** Founders Online (National Archives) could not be fetched because of a bot challenge, so the letters are cited from the public-domain Gutenberg editions; a 1786 lead letter transcription on another site was not used. The roster's psoriasis, pleurisy as an anchor condition, skin conditions, and presbyopia were not pursued; the past pleurisies are recorded as history only. A secondary statement that gout kept him from most sessions as a Pennsylvania delegate was seen on the birth-date source but is not used. Laudanum in his last year is recorded as history and does not enter the synthetic medication list.
- **Sick and wellness visits.** The sick visit is a crystal-proven gout flare of the left knee during allopurinol titration, chosen because flares are common in the first months of urate lowering and because it teaches flare treatment with CKD (a short prednisone course, no NSAIDs, allopurinol continued) and aspiration of a new large joint. It does not echo a dated historical attack. The wellness visit adds a synthetic positive AUDIT-C (4) with brief counseling, which is not an alcohol use disorder diagnosis, and its advance care planning names no real person.
- **Focused visits.** The three chronic-care follow-ups (four weeks, eleven weeks, and about six months) are documented as focused visits on the ACR gout and AUA/EAU stone guidelines and the CMID hypertension, chronic kidney disease, and BPH monographs. Four deviations are recorded as `deferred`, each with its outcome and corrective action, and no result was invented: the urate check two to five weeks after the first allopurinol increase (drawn at seven weeks, because surgery intervened); the urate check after the second increase (first drawn at the flare visit at seven weeks); the potassium check two to four weeks after starting potassium citrate with losartan (first drawn at seven weeks); and the three-month post-procedural urologic check (no separate visit).
- **Consultation.** The urology referral and consultation are synthetic. The cystoscopy, uroflowmetry, and residual on the consultation day are the record's procedures and results. Its recommendations match what followed: combined cystolitholapaxy and transurethral resection, tamsulosin until surgery, no PSA, post-operative urinalysis and 24-hour urine, potassium citrate with potassium monitoring, and IPSS and residual checks after surgery.
- Franklin died in 1790, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
